News (2020)

Archive:
  • Archives

  • TOPADUR under the eleven Swiss start-ups on the virtual BIO Digital stage !

    28.05.2020 / Media

    Even in the absence of physical presence, trade fairs are taking place in new formats. One of such events is the International Convention BIO, which turned into Bio Digital. At the upcoming online event from 8 -12 June 2020, more than 2300 companies from all over the world and start-ups will attend to learn and […]

    read more

    Scientific Publication in the Journal of Investigative Dermatology

    20.05.2020 / Media

    May 20, 2020 We are happy to announce that on May 18, 2020, under the title “A dual-acting nitric oxide donor and phosphodiesterase 5 inhibitor promotes wound healing in normal and diabetic mice” (JID-2019-0913.R1) the Journal of Investigative Dermatology accepted a manuscript for publication as confirmed by their Principal Deputy Director Thomas Krieg, MD. ABSTRACT […]

    read more

    TOPADUR Pharma Germany GmbH founded.

    20.05.2020 / Media

    For our first clinical trial in the EU, TOPADUR Pharma Germany GmbH, located at Georges-Köhler-Str. 2 in Lörrach, Germany, was entered in the company register in May 2020. Dr. Reto Näf and Dr. Christian Ludin act as our managing directors.

    read more

    Clinical Trial Application (CTA) documents filed – another significant TOPADUR milestone to our first clinical study !

    20.05.2020 / Media

    Dear TOPADUR followers, We are proud to announce that another important milestone of our dynamic young start-up was achieved on May 11, 2020. The application documents (Clinical Trial Application – CTA) for approval of our phase 1 study for diabetic foot ulcer (DFU) have been submitted to the authorities and the ethics committee.

    read more

    TOPADUR mentioned in Innosuisse Annual Report 2019

    08.05.2020 / Media

    Glaucoma is the second most common cause of blindness after cataracts, with over 100,000 people suffering from glaucoma in Switzerland and over 64 million people worldwide.  With its latest research, TOPADUR, with the support of Innosuisse and in collaboration with the University of Zurich and the Institute for Molecular and Clinical Ophthalmology of the University […]

    read more